| Title |
Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, January 2021
|
| DOI | 10.1158/1535-7163.mct-20-0480 |
| Pubmed ID | |
| Authors |
Shauni Lien Geeraerts, Kim Rosalie Kampen, Gianmarco Rinaldi, Purvi Gupta, Mélanie Planque, Nikolaos Louros, Elien Heylen, Kaat De Cremer, Katrijn De Brucker, Stijn Vereecke, Benno Verbelen, Pieter Vermeersch, Joost Schymkowitz, Frederic Rousseau, David Cassiman, Sarah-Maria Fendt, Arnout Voet, Bruno P.A. Cammue, Karin Thevissen, Kim De Keersmaecker |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 2 | 18% |
| United States | 1 | 9% |
| France | 1 | 9% |
| Belgium | 1 | 9% |
| Unknown | 6 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Scientists | 1 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 14% |
| Researcher | 9 | 12% |
| Student > Bachelor | 8 | 11% |
| Unspecified | 6 | 8% |
| Other | 3 | 4% |
| Other | 11 | 15% |
| Unknown | 27 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 16 | 22% |
| Medicine and Dentistry | 9 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 7% |
| Unspecified | 4 | 5% |
| Other | 8 | 11% |
| Unknown | 26 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 145. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2023.
All research outputs
#286,887
of 25,483,400 outputs
Outputs from Molecular Cancer Therapeutics
#31
of 4,070 outputs
Outputs of similar age
#8,290
of 520,616 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 58 outputs
Altmetric has tracked 25,483,400 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,070 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 520,616 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.